VERICEL CORPORATION - COMMON STOCK

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

05 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results

09 Jan 2024 06:55:00 By Nasdaq GlobeNewswire

Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

03 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

08 Nov 2023 06:55:00 By Nasdaq GlobeNewswire

Vericel to Present at the Stephens Annual Investment Conference

07 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

25 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid

28 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

20 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Morgan Stanley Global Healthcare Conference

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

02 Aug 2023 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023

20 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

10 May 2023 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023

26 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

28 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance

23 Feb 2023 06:55:00 By Nasdaq GlobeNewswire

Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

09 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

10 Jan 2023 06:55:00 By Nasdaq GlobeNewswire

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

04 Jan 2023 07:34:47 By Nasdaq GlobeNewswire

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

29 Dec 2022 12:45:00 By Nasdaq GlobeNewswire

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

10 Nov 2022 08:00:01 By Nasdaq GlobeNewswire